



## NEWS RELEASE

# Vir Biotechnology to Present at J.P. Morgan 2024 42nd Annual Healthcare Conference

12/6/2023

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Vir's Chief Executive Officer, will present at the J.P. Morgan 2024 42<sup>nd</sup> Annual Healthcare Conference on Wednesday, January 10, at 3:45 p.m. PT / 6:45 p.m. ET.

A live webcast of the presentation can be accessed under Events & Presentations in the Investors section of the Vir website at [www.vir.bio](http://www.vir.bio) and will be archived there for 30 days.

## About Vir Biotechnology

Vir Biotechnology, Inc. is an immunology company focused on combining cutting-edge technologies to treat and prevent infectious diseases and other serious conditions. Vir has assembled two technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current clinical development pipeline consists of product candidates targeting hepatitis delta and hepatitis B viruses and human immunodeficiency virus. Vir has several preclinical candidates in its pipeline, including those targeting influenza A and B, COVID-19, RSV/MPV and HPV. Vir routinely posts information that may be important to investors on its website.

## Media

Carly Scaduto

Senior Director, Media Relations

[cscaduto@vir.bio](mailto:cscaduto@vir.bio)

+1 314-368-5189

## Investors

Sasha Damouni Ellis

Executive Vice President, Chief Corporate Affairs Officer

**sdamouni@vir.bio**

Source: Vir Biotechnology, Inc.